Kawasumi Laboratories Inc. announced consolidated earnings results for the six months ended September 30, 2016. For the period, the company reported net sales of ¥12,287 million, operating income of ¥571 million, ordinary income of ¥467 million, profit attributable to owners of the parent of ¥636 million or net income per share of ¥29.16 compared to net sales of ¥13,982 million, operating income of ¥984 million, ordinary income of ¥1,070 million, net income of ¥787 million or net income per share of ¥34.43 for the same period last year. Profit before income taxes was ¥465 million against ¥1,087 million a year ago. Net cash provided by operating activities was ¥1,765 million against ¥1,742 million a year ago. Purchase of property, plant and equipment was ¥743 million against ¥212 million a year ago. Purchase of intangible assets was ¥120 million against ¥21 million a year ago.

The company declared second quarter end dividend for the fiscal year 2017 of ¥7.50 per share against same amount a year ago. The dividend is payable on December 5, 2016.

The company provided dividend guidance for the year end of fiscal year ending March 31, 2017. For the period, the company expects dividend of ¥7.50 per share against ¥7.50 per share a year ago.

For the full year of fiscal year ending March 31, 2017, the company expects consolidated net sales of ¥25,700 million, operating income of ¥1,150 million, ordinary income of ¥1,150 million, profit attributable to owners of the parent of ¥1,200 million or net income per share of ¥55.01.